NSEAcquisition28 Sept 2026 · 28 Sept 2026, 09:20 pm

Acquisition

Indoco Remedies Limited · INDOCO

✦ AI SummaryJoint Venture

Indoco Remedies Limited has informed the Exchange about the incorporation of a Wholly Owned subsidiary, Warren Lifesciences Private Limited, under the provisions of the Companies Act, 2013.

Analysis Scores

Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Indoco Remedies Limited has informed the Exchange about the incorporation of Wholly Owned subsidiary of the Company in the name and style of "Warren Lifesciences Private Limited .

Attachments (1)

📄

INDOCO_28092026211330_Intimation_Incorporation_Subsidiary_-.pdf

pdf

Download →
View document text
Date: 28th September, 2026 To To The Listing Department The Listing Department National Stock Exchange of India Limited Bombay Stock Exchange Limited Exchange Plaza, Floor 25, P. J. Towers, Bandra – Kurla Complex Dalal Street, Bandra (East) Mumbai – 400 001 Mumbai – 400 051 Stock Code : 532612 Stock Code : INDOCO Dear Sir/Madam, Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of Wholly Owned Subsidiary We refer to our letter dated 18th September, 2026 wherein we informed about the Committee of Executive Director’s approval for the incorporation of the wholly owned subsidiary of the Company. In continuation to the aforesaid letter and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the Company received intimation today that the Wholly Owned Subsidiary of the Company in the name and style of “Warren Lifesciences Private Limited” has been incorporated on 26th September, 2026 under the provisions of the Companies Act, 2013. Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated 30th January, 2026 are enclosed as Annexure A. You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Indoco Remedies Limited Ramanathan Hariharan Company Secretary & Head Legal Annexure A Sr. No. Particulars Details 1 Name of the target entity, details in Name of the Target Entity brief such as size, turnover etc.; Warren Lifesciences Private Limited (WLPL) WLPL has authorised share capital of Rs. 1,00,000 divided into 10,000 equity shares of Rs. 10/- each. Size/Turnover: Not applicable as the Company is newly incorporated on 26th September, 2026 2 Whether the acquisition would fall Being a wholly owned subsidiary, WLPL is a within related party transaction(s) related party of Indoco Remedies Limited. and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”; 3 Industry to which the entity being Pharmaceutical Sector acquired belongs; 4 Objects and impact of acquisition WLPL is incorporated with the object to (including but not limited to, manufacture, develop, sell etc. disclosure of reasons for acquisition pharmaceutical products including but not of target entity, if its business is limited to active pharmaceutical outside the main line of business of ingredients, finished formulations, key the listed entity); starting materials. 5 Brief details of any governmental or Not Applicable as this intimation is about regulatory approvals required for incorporation the acquisition; 6 Indicative time period for Not Applicable as this intimation is about completion of the acquisition; incorporation 7 Consideration - whether cash Subscription of shares in WLPL will be by consideration or share swap or any way of cash consideration. other form and details of the same 8 Cost of acquisition and/or the price 10,000 equity shares of WLPL will be at which the shares are acquired; subscribed at face value of Rs. 10 per share. 9 Percentage of shareholding / control WLPL is incorporated with the authorised acquired and / or number of shares share capital of Rs. 1,00,000 divided into acquired; 10,000 equity shares of Rs. 10/- each. The entire paid-up share capital (i.e. 100% of the shareholding) of WLPL will be held by Indoco Remedies Limited. 10 Brief background about the entity Terms of products/line of business: acquired in terms of products/line of WLPL will manufacture, develop, sell etc. business acquired, date of pharmaceutical products including but not incorporation, history of last 3 years limited to active pharmaceutical turnover, country in which the ingredients, finished formulations, key acquired entity has presence and starting materials. any other significant information (in brief); Date of incorporation: WLPL is incorporated in India and is registered with the Registrar of Companies, Mumbai, Maharashtra on 26th September, 2026 and is yet to commence its business operations. History of last 3 years turnover: Not Applicable as newly incorporated company. Country in which the acquired entity has presence: India